WO2013165972A3 - Anticorps anti-virus hépatite b et applications associées - Google Patents

Anticorps anti-virus hépatite b et applications associées Download PDF

Info

Publication number
WO2013165972A3
WO2013165972A3 PCT/US2013/038802 US2013038802W WO2013165972A3 WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3 US 2013038802 W US2013038802 W US 2013038802W WO 2013165972 A3 WO2013165972 A3 WO 2013165972A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
sample
virus
detecting
binding agent
Prior art date
Application number
PCT/US2013/038802
Other languages
English (en)
Other versions
WO2013165972A2 (fr
Inventor
Shuji Sato
Sean Andre BEAUSOLEIL
Wan Cheung CHEUNG
Roberto D. POLAKIEWICZ
Original Assignee
Cell Signaling Technology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology, Inc. filed Critical Cell Signaling Technology, Inc.
Publication of WO2013165972A2 publication Critical patent/WO2013165972A2/fr
Publication of WO2013165972A3 publication Critical patent/WO2013165972A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des anticorps anti-virus hépatite B et des méthodes de traitement, de prophylaxie, de détection et de diagnostic associées.
PCT/US2013/038802 2012-04-30 2013-04-30 Anticorps anti-virus hépatite b et applications associées WO2013165972A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640361P 2012-04-30 2012-04-30
US61/640,361 2012-04-30
US201361787143P 2013-03-15 2013-03-15
US61/787,143 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013165972A2 WO2013165972A2 (fr) 2013-11-07
WO2013165972A3 true WO2013165972A3 (fr) 2014-02-27

Family

ID=49515018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/038802 WO2013165972A2 (fr) 2012-04-30 2013-04-30 Anticorps anti-virus hépatite b et applications associées

Country Status (1)

Country Link
WO (1) WO2013165972A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936877C (fr) * 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Anticorps monoclonaux humains neutralisants diriges contre l'antigene de surface du virus de l'hepatite b
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
AU2016297248A1 (en) * 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
MX2018003196A (es) 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
KR20180094110A (ko) 2016-01-08 2018-08-22 스칼러 락, 인크. 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20230028813A (ko) 2016-06-13 2023-03-02 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
WO2018039514A1 (fr) * 2016-08-25 2018-03-01 Vanderbilt University Anticorps pour la neutralisaton du virus ebola.
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (fr) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production d'anticorps monoclonaux humains actifs contre l'antigene de surface de l'hepatite b
WO2004050683A2 (fr) * 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (fr) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Protéine de fusion anticorps anti-cmh cytokine antivirale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011495A1 (fr) * 1992-11-06 1994-05-26 Sandoz, Ltd. Production d'anticorps monoclonaux humains actifs contre l'antigene de surface de l'hepatite b
WO2004050683A2 (fr) * 2002-12-02 2004-06-17 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
US20080152658A1 (en) * 2005-04-18 2008-06-26 Shlomo Dagan Stabilized Anti-Hepatitis B (Hbv) Antibody Formulations
WO2012017003A1 (fr) * 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Protéine de fusion anticorps anti-cmh cytokine antivirale

Also Published As

Publication number Publication date
WO2013165972A2 (fr) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2013165972A3 (fr) Anticorps anti-virus hépatite b et applications associées
WO2014015194A3 (fr) Procédés de détection et de mesure d'agrégation
MX2020009021A (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco.
WO2013070776A8 (fr) Anticorps neutralisant la gp41 et leur utilisation
AU2018200278B2 (en) Antibodies to aripiprazole and use thereof
WO2012100235A3 (fr) Systèmes et procédés de maximisation d'utilisation d'échantillon
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
EP3933406A3 (fr) Anticorps pour rispéridone et utilisation associée
WO2014165082A3 (fr) Anticorps et procédés de détection
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
BR112012016119A2 (pt) detecção de carga biológica viva com o uso de micropartículas
WO2012054588A3 (fr) Dispositifs à conduits et procédés de détection et de traitement d'analytes
GB2519906A (en) Methods and systems for detecting biological components
WO2014031668A3 (fr) Anticorps dirigés contre la quétiapine et leur utilisation
PL2821415T3 (pl) Przeciwciało przeciwko lipoarabinomannanowi i test immunologiczny do oznaczania zakażenia kwasoopornymi prątkami przy użyciu tego przeciwciała
WO2012129164A3 (fr) Biocapteur
WO2014031662A3 (fr) Anticorps dirigés contre l'olanzapine et leur utilisation
MX336109B (es) Formacion de imagenes inmuno-tep de anticuerpos e inmunoconjugados y usos de lo mismo.
MX2016005686A (es) Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
EP2950099A4 (fr) Méthode de prétraitement d'échantillon pour la détection d'antigène hbs, et utilisation associée
IT201600073964A1 (it) Nanointerruttore basato su nucleotidi e metodi per la rilevazione di anticorpi e altri analiti
MX2015004419A (es) Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables.
TWI800483B (zh) 抗人類血紅素單株抗體或抗體套組、抗人類血紅素單株抗體固定化不可溶性載體粒子、及使用其等之測定試劑或測定方法
EP3004375A4 (fr) Biocapteurs peptidiques sensibles à une protéase et procédés de détection d'analyte
WO2012032512A3 (fr) Procédés et kits pour la détection d'une infection chez des sujets présentant de faibles teneurs en anticorps spécifiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13784796

Country of ref document: EP

Kind code of ref document: A2